Overview

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Status:
Completed

Trial end date:
2018-12-12

Target enrollment:

Participant gender:

Summary

This is a study to determine the clinical benefit (how well the drug works), safety, and tolerability of combining varlilumab and nivolumab (also known as Opdivo® , BMS-936558). Both drugs target the immune system and may act to promote anti-cancer effects.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Celldex Therapeutics

Collaborator:

Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Nivolumab